Journal of comparative effectiveness research · 2019
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
Клиническое исследование IV фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zivadinov Robert, Kresa-Reahl Kiren, Weinstock-Guttman Bianca, Edwards Keith, Burudpakdee Chakkarin, Bergsland Niels, Dwyer Michael G, Khatri Bhupendra, Thangavelu Karthinathan, Chavin Jeffrey, Mandel Matt, Cohan Stanley
Аннотация
AIM: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted.
OBJECTIVES: To compare the real-world effectiveness of TFM versus DMF.
METHODS: Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50) or DMF (N = 50).
RESULTS: On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p = 0.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p = 0.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals.
CONCLUSION: The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI/clinical end points.
OBJECTIVES: To compare the real-world effectiveness of TFM versus DMF.
METHODS: Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50) or DMF (N = 50).
RESULTS: On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p = 0.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p = 0.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals.
CONCLUSION: The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI/clinical end points.
Предметные рубрики MeSH
AdolescentAdultAgedBrainComparative Effectiveness ResearchCrotonatesDimethyl FumarateFemaleHumansHydroxybutyratesImmunosuppressive AgentsLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingNitrilesRetrospective StudiesSingle-Blind MethodSocioeconomic FactorsToluidinesYoung Adult